Genmab — August 2023
-
Det går den rigtige vej...den skal da også have lidt fart på hvis 2800 skal rundes medio sep.
-
Medicinalbranchen holder vejret: Ti store lægemidler skal have forhandlet pris i USA https://www.proinvestor.com/investornyt/1041121/medicinalbranchen-holder-vejret-ti-store-laegemidler-skal-have-forhandlet-pris-i-usa
-
Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference https://www.proinvestor.com/investornyt/1041205/genmab-to-present-at-morgan-stanley-21st-annual-global-healthcare-conference
-
small new Dara trial; The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC). https://clinicaltrials.gov/study/NCT06015724?tab=table
-
Endelig et indlæg idag
Tak for det, @EL. -
Kan ikke mindes nogen dag, overhovedet, hvor der har været så lidt trafik på PI’s chats….. Og det endda til trods for, at det faktisk blev en ret god børsdag.
-
Jep
-
Måske forventet, men dara var ikke på IRA drug listen https://www.hhs.gov/about/news/2023/08/29/hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation.html
-
Interessant. IRA drug listen vil blive fornyet årligt, så det kan jo være dara kommer med på et tidspunkt: "In future years, CMS will select for negotiation up to 15 more drugs covered under Part D for 2027, up to 15 more drugs for 2028 (including drugs covered under Part B and Part D), and up to 20 more drugs for each year after that, as outlined in the Inflation Reduction Act"
-
J&J har 3 produkter på listen til prisforhandling, men listen er ikke noget der påvirker de pågældende firmaers aktiepris synderligt idag: https://www.statnews.com/2023/08/29/10-drugs-medicare-price-negotiation/
-
New Genmab trial: A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma https://clinicaltrials.gov/study/NCT06018129
-
Brief Summary:
The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory (R/R) CD30-expressing lymphomas.GEN3017 will be administered via subcutaneous injections
CD3xCD30Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind